

South Korea Invests \$261 Million Into New mRNA Factory Located in a "Smart City", Will Produce New mRNA Vaccines Within 100 Days in Partnership with Gates Foundation

South Korea is a model of mRNA failure, and cancer cases are on the rise...

By <u>Dr. William Makis</u> Global Research, February 14, 2023 <u>COVID Intel</u> Region: <u>Asia</u> Theme: <u>Science and Medicine</u>

All Global Research articles can be read in 51 languages by activating the **Translate Website** button below the author's name (desktop version)


To receive Global Research's Daily Newsletter (selected articles), click here.


Follow us on <u>Instagram</u> and <u>Twitter</u> and subscribe to our <u>Telegram Channel</u>. Feel free to repost and share widely Global Research articles.

South Korea claims a **85.8%** fully COVID-19 vaccinated rate, with over **130.6 million** doses administered (Pfizer 62%, Moderna 20%, AZ 16%, JJ 1%) (<u>click here</u>).

It is a model of COVID-19 mRNA vaccine failure.

South Korea's COVID-19 booster rollout appears to have driven ever increasing waves of COVID-19 infection and death throughout 2022 and into 2023 (<u>click here</u>).





Doubling down on mRNA vaccine failure:

On Feb.8, 2023, Korean news reported that SK bioscience will invest **\$258 million** to build a manufacturing facility "aiming to become a key player in the vaccine industry" (click here)

"SK bioscience cooperated with **Bill & Melinda Gates Foundation** to develop **SKYCovione**, Korea's first domestically-developed COVID-19 vaccine.

The facility is not only for the vaccine but also **cell and gene therapy and mRNA technology**"

It gets more interesting:

Fierce biotech reports (<u>click here</u>): "SK bioscience...plans to invest \$261 million in a R&D hub designed to establish it as a leading force in the **global response to new infectious diseases**"

"The South Korean company put the planned global research and process development center in **Songdo, a so-called smart city 18 miles from Seoul**", at the heart of the strategy...total outlay of \$261 million to support the creation of a vaccine/biopharmaceutical hub on the **320,000 square foot site**.

"Completion is scheduled for the first half of 2025. Once the site is ready, SK bioscience will

relocate its headquarters...to help the company **preemptively respond to emerging** infectious diseases.

"The establishment of the R&PD Center will be a crucial milestone for us to advance the entire vaccine and biopharmaceutical industry **beyond Korea to the world**"

"SK bioscience manufactured COVID-19 vaccines for AstraZeneca and Novavax"

Making new mRNA vaccines within 100 days with Gates Foundation:

SK Bioscience press release Nov.2022 (<u>click here</u>): "Through securing the **mRNA technology**, product development, and platform expansion, SK bioscience plans to establish a system that can **develop vaccines against new infectious diseases within 100 days and supplies them within 6 months with global partners, including Bill & Melinda Gates Foundation, CEPI, and Hilleman Laboratories**."

"SK bioscience also operates 'Glocalization' project which transfers vaccine development, manufacturing, and production capabilities to each government and partner companies in the world to establish a vaccine manufacturing infrastructure for the needs in each region"

Tripling of cancer cases in Korea since mRNA rollout?

There seems to be some controversy around alleged tripling of cancer cases in South Korea in 2022 "due to COVID-19 vaccines" (<u>click here</u>)

A Facebook post showed a photo of a datasheet titled: "Massive spike in patients diagnosed with cancer after Covid vaccinations".

The datasheet is credited to South Korea's Health Insurance Review and Assessment Service (HIRA), a government agency responsible for reviewing and evaluating healthcare costs and services.

The document says there were between 1.2 million and 1.5 million new cancer cases every year between 2016 and 2021, but that this shot up to more than 3 million new cancer cases in 2022 — the year after South Korea began its Covid-19 vaccine roll-out in February 2021.

While South Korea's government health insurance agency denies the claim, they don't deny the increased numbers, only what those numbers mean:

"The numbers seen in this chart represent the number of patients who filed health insurance claims related to cancer each corresponding year, not the number of new cancer patients," the spokesperson told AFP on February 3."

"A claim may be recorded each time a person visits the hospital to be treated for cancer, and a patient may visit the hospital several times a year," they added.

"data for 2021 and 2022 would be released towards the end of the year."

My take....

It is clear that no matter how much mRNA fails, big pharma continues to invest 100s of

millions of dollars building new mRNA facilities.

This one is straight out of a dystopian novel. A 320,000 sq ft mRNA factory located in a "smart city" that can produce new mRNA vaccines within 100 days in partnership with Gates Foundation against "new infectious diseases"?

That should concern everyone.

Also, the tripling of cancer related insurance claims isn't adequately explained by Korean government officials. I suspect cancer cases are skyrocketing and the Korean government is holding back the 2021 and 2022 data on "number of new cancer patients" for a good reason.

*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

The original source of this article is <u>COVID Intel</u> Copyright © <u>Dr. William Makis</u>, <u>COVID Intel</u>, 2023

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Dr. William Makis

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca